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activities (binding affinities and target proteins) will cre-
ate a fingerprint against which future molecules may be
compared. One can envisage the optimization of kinase
inhibitors for activity against a specific subset of kinase
targets or a particular signaling pathway that has been
associated with the biological effect of interest. Impor-
tantly, these affinity-based techniques are not limited
to compounds that bind to an enzyme active site, but
in principle could be extended to allosteric inhibitors
and inhibitors of proteins that lack a catalytic function.
Affinity chromatography and Y3H are complemen-
tary, since each is subject to different limitations includ-
ing the use of cell lysate versus intact live cells, the use
of mammalian versus yeast cells, and very likely differ-
ent influences attributable to protein expression levels.
Both techniques are limited by the requirement to mod-
ify chemically or to immobilize the biologically active
probe molecule. Y3H shares an advantage with display
cloning, namely that identification of the target protein is
linked to identification of the corresponding gene, facil-
itating its identification and subsequent protein over-
expression. The visual read-out from Y3H (cell growth),
and its potential for automation at many steps, offers
considerable potential for parallel screens against dif-
ferent proteomes, multiple protein classes, or mutants
of the same protein. The selection of compounds match-
ing a specific binding profile from a library of
potential inhibitors also is conceivable. The future ex-
tension of three-hybrid technology to mammalian cells
will expand the scope of compounds that can be used,
increase the potential for competition assays, as well
as provide a more direct relationship to phenotypic data
from mammalian cells. As such powerful tools become
increasingly available, it no longer will be sufficient to fo-
cus on a small number of proteins in evaluating inhibitor
selectivity. Chemical tools will have to meet a higher
standard of characterization, and we all may have to
be more circumspect in our use of the word ‘‘selective.’’
Peter L. Toogood
Pfizer Global Research and Development
Michigan Laboratories
2800 Plymouth Road
Ann Arbor, Michigan 48105
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Figure 1. Schematic of a Yeast Three-Hybrid System
Transcription factor DNA binding (BD, dark blue) and activation
(AD, light blue) domains are fused to DHFR (red) and an expressed
library of proteins (green), respectively. A library of chemical dimer-
izers comprised of methotrexate (black) and a candidate small mol-
ecule (yellow) joined by a linker has the potential to bind to both
DHFR and the unknown, target protein. Binding reconstitutes the
transcription factor activity leading to expression from a reporter
gene promoter (gray) and an observable phenotype. Figure pro-
vided by L. Szewczak.
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that cellularization remains integral to myogenic de-
differentiation, but is insufficient for reentry of the
mononucleate progeny into the cell cycle.
For decades, researchers have examined in great
detail the mechanisms underlying the spontaneousSmall Molecules
Driving Myotube Fission
In this issue of Chemistry & Biology, Duckmanton
et al. [1] have rigorously studied myotube fragmenta-
tion, or ‘‘cellularization,’’ triggered by microtubule-
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1059dedifferentiation of postmitotic cells into malignant
cancer cells in an effort to design ways in which to
counter their hyperproliferation. Such efforts have led
to the development of drugs that target the mitotic
spindle [2] or inhibit proteasomes [3] or alter the cova-
lent modification of small GTP binding proteins (i.e.,
p21ras) [4]. These drugs all share the ultimate goal of in-
terfering with cell cycle progression in these proliferat-
ing, pathological cells. The antithesis of this line of
investigation is that there exist other pathological states
(e.g., tissue degenerative diseases, severe wounding,
etc.) where it would be of enormous therapeutic benefit
to deliberately reactivate the cell cycle within fully differ-
entiated but quiescent cells in order to bring about
tissue regeneration. The discovery and development
of small molecules to realize this goal is understandably
still in its infancy.
Few models of nonpathological cell dedifferentiation
exist in higher organisms, with the process of limb re-
generation in the urodele amphibian arguably being
the best studied. A deliberate and carefully controlled,
but nonetheless poorly understood, program of cell de-
differentiation is utilized by urodele amphibians (i.e.,
newts and axolotls) to begin regeneration of damaged
or missing body structures (e.g., limbs, tail, etc.). Fully
differentiated, postmitotic muscle tissue and other tis-
sues adjacent to a wound or amputation are induced
to reenter the cell cycle to form a rapidly proliferating
mass of undifferentiated cells referred to as the ‘‘blas-
tema.’’ Over time, the blastema gradually regenerates
the missing body structure. The process of limb regen-
eration had historically been well studied in urodeles
both from a phenomenological [5] as well as an anatom-
ical viewpoint [6]—yet only recently has it been investi-
gated at the cellular and biochemical levels.
Jeremy Brockes and coworkers pioneered a shift in
the study of cell dedifferentiation from the organism it-
self into the more easily manipulated realm of the tissue
culture dish. Through use of cultured newt muscle cells
and injectable markers, they have previously shown not
only that newt myoblasts (muscle cell progenitors)
could be differentiated in vitro into multinucleate myo-
tubes [7], but also that these same cultivated newt my-
otubes could be biochemically labeled and surgically
implanted into early newt limb blastema to give rise to
mononucleate cells in vivo—within the regenerated limb
[8]. The question was posed then as to the role of
fragmentation, or cellularization, of the multinucleate
myotube in the context of dedifferentiation: was cellula-
rization an early and causal step in the process of cell
dedifferentiation, or merely one downstream conse-
quence of an upstream signal for dedifferentiation?
Brockes and coworkers reasoned that since urodele
regeneration typically requires wounding and hemosta-
sis [9], thrombin might play a role in activating dediffer-
entiation. Subsequently, in Tanaka et al. they showed
that cultured newt myotubes were stimulated to reenter
the cell cycle upon application of thrombin-treated
serum [10]. This thrombin-activated dedifferentiating
activity was present in the blood serum from many ver-
tebrate species, thereby indicating that certain elements
of the regeneration program might yet be preserved in
mammals. Efforts continue toward the purification and
identification this latent serum factor [11].Shortly thereafter, McGann et al. [12] were the first
to reveal that differentiated mammalian myotubes do
indeed possess the capability to reenter the cell cycle
as well. Treatment of cultured, isolated mouse myo-
tubes with an extract prepared from newt blastemas
not only resulted in detectable incorporation of the nu-
cleotide 5-bromo-20-deoxyuridine (BrdU) into the nuclei
of these myotubes, but also stimulated fission of the
multinucleated tubes into mononucleate progeny cells.
Although the highly specialized and limiting nature of
the blastema starting material has made traditional
biochemical purification of the responsible factor(s) a
daunting endeavor, the demonstration that mammalian
myotubes may undergo dedifferentiation and cellu-
larization similar to their amphibian counterparts was
very encouraging. The results of these studies involving
blastema extract and thrombin-treated serum have
spurred the search for small molecules capable of trig-
gering myogenic dedifferentiation in mammalian sys-
tems. The first small molecule identified from screens
of chemical libraries was a trisubstituted purine that
seemed capable of triggering fission of differentiated
murine myotubes into actively proliferating myoblasts
[13]. ‘‘Myoseverin,’’ as it was aptly named, was found
to bind tubulin and disintegrate the highly ordered mi-
crotubule cytoskeleton within the myotube, resulting
in cytokinesis surrounding the nuclei. Initial studies
involving myoseverin also reported that these result-
ing mononucleates were capable of incorporating BrdU,
consistent with the notion that they were able to prolif-
erate following fission [13, 14]. This result supported the
view that cellularization might be sufficient to trigger
myogenic dedifferentiation, a surprising and somewhat
unexpected result that is meticulously revisited in the
study described herein [1].
In this issue of Chemistry & Biology [1], Duckmanton
et al. use time-lapse photography of fully differentiated,
isolated mouse myotubes to document that myoseverin,
as well as nocodozole and their own newly created
triazine-based small molecule, can instigate their cel-
lularization into mononucleate cells. These mononu-
cleates are still competent to re-fuse into myotubes
upon withdrawal of the microtubule depolymerizer; how-
ever, they are incapable of dividing and proliferating as
assessed by BrdU incorporation and centriole examina-
tion. Microarray analysis of changes in mRNA levels in-
duced by the active molecules and their inactive iso-
mers detected few consensus increases or decreases
in gene expression, suggesting that microtubule depoly-
merizers are insufficient to cause the full program of de-
differentiation.
The innovation of this report is the considered appli-
cation of existing technologies to more carefully inspect
the effects of this class of molecules. The authors have
worked extensively with cultured myotubes of both am-
phibian as well as mammalian lineage, and they recog-
nized that myoblast to myotube fusion is less than
quantitative. Thus, in order to obtain an enriched popu-
lation of differentiated myotubes, the remaining myo-
blasts were filtered away using nylon microsieves that
selectively retain the myotubes. On top of that, the
authors relied on time-lapse photography and stain-
ing for myosin heavy chain to unambiguously identify
mononucleates as progeny of treated myotubes. These
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nating, undifferentiated myoblasts which quite likely
contributed to the confusion regarding the activity
of microtubule depolymerizing agents in myogenic de-
differentiation.
More recent studies have identified other agents,
which seem more certain to induce dedifferentiation in
vitro. ‘‘Reversine’’ is a small molecule that can trigger
myoblasts, which are lineage committed, to dedifferen-
tiate into more multipotent progenitor-type cells which
are capable of being directed to differentiate not only
into osteoblasts but adipocytes as well [15]. Such dis-
coveries have not been limited to small molecules: Chen
et al. recently showed that ciliary neurotrophic factor
(CNTF) can similarly induce myoblasts to adopt a
multipotent phenotype capable of redifferentiating into
adipocytes, glial, and neuronal cells [16]. It remains
to be determined whether reversine and CNTF share a
common mechanism or have an effect on the more
differentiated myotube. Perhaps a combination of a
microtubule depolymerizer and reversine might accom-
plish that which the former, and agents like it, alone
cannot—complete cellularization and dedifferentiation
of mammalian myotubes.
John Hines
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The Stereochemistry
of Ketoreduction
In this issue of Chemistry & Biology, Leadlay and co-
workers [1] report overproduction of a number of keto-
reductase domains frommodular polyketide synthases.
These discrete enzymes allow the stereochemistry of
polyketide ketoreduction to be studied in isolation.
The well-studied 6-deoxyerythronolide B synthase
(DEBS) catalyzes formation of the macrolactone core
of erythromycin [2]. DEBS contains a module for each
of the six cycles in the chain assembly process. This
modular organization is found in many other important
polyketide synthases (PKSs) [3]. In a typical module,
an acyl transferase (AT) loads an extender unit onto
the phosphopantetheine thiol of an acyl carrier protein
(ACP). The extender condenses with an acyl chain that
is thioester-linked to the active site cysteine of a keto-
synthase (KS). The resulting b-ketoacyl-ACP may beSelected Reading
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reduced to a b-hydroxyacyl intermediate by a keto-
reductase (KR) and may be processed further by dehy-
dratase and enoyl reductase enzymes. An entire PKS
consists of a series of modules that are housed within
large multienzyme polypeptides. A frequently occurring
module catalyzes the incorporation of propionate, and
reduction of the b-ketone group to an alcohol. The 2-
methyl-3-hydroxyacyl thioester product has two new
chiral centers. All four combinations of methyl and alco-
hol stereochemistry [(2R, 3S), (2S, 3R), (2R, 3R), (2S, 3S)]
can appear in nascent polyketide chains. It is unclear
how these different stereochemical outcomes are
achieved by PKS modules of apparently similar domain
composition and sequence.
Detailed studies on DEBS and truncated derivatives
have given deep insights into the stereochemistry of
polyketide chain extension. All six modules use (2S)-
methylmalonyl-CoA as a source of activated propionyl
extender units [4]. In the cycle catalyzed by DEBS
module 2, condensation proceeds with inversion of ste-
reochemistry, so that the initial product is (2R)-
2-methyl-3-ketoacyl-ACP2 [5]. With DEBS module 1, the
